HOME - OUR SCIENCE - Pipeline - ES014

ES014, a dual acting molecule that binds CD39 and Target 2 (undisclosed). It inhibits ATPase activity and target immunosuppressive pathways to promote anti-tumor responses and efficacy. Now, ES104 is currently being evaluated in IND-enabling studies.


ES014 targets proteins that support tumor growth and major roadblocks to anti-tumor immunity. Blocking these two pathways simultaneously to to address therapeutic resistance to immune checkpoint blockade and other therapeutic approaches.